Answers are grounded in this paper and cite their sources.
Demonstrates tumor growth arrest in mice using nanoparticle vaccination to activate CD8+ dendritic cells, highlighting potential for immunotherapy.
Aim: We wanted to assess the potency of a trifunctional nanoparticle (NP) that targeted and activated CD8+ dendritic cells (DC) and delivered an antigen to induce antitumor responses. Materials & methods: The DC targeting and activating properties of ferrous NPs conjugated with immunostimulatory CpG-oligonucleotides, anti-DEC205 antibody and ovalbumin (OVA) as a model antigen to induce antigen-specific T-cell responses and antitumor responses were analyzed. Results: OVA-loaded NP conjugated with immunostimulatory CpG-oligonucleotides and anti-DEC205 antibody efficiently targeted and activated CD8+ DC in vivo, and induced strong OVA-specific T-cell activation. Vaccination of B16/OVA tumor-burdened mice with this NP formulation resulted in tumor growth arrest. Conclusion: CD8+ DC-targeting trifunctional nanocarriers bear significant potential for antitumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: